Stay updated with breaking news from Patient Support Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ -- Taiwan-based digital health startup Health2Sync makes further inroads in personalized chronic disease management with an expanded coverage of...
Learn more about the importance of N95 and K95 masks for better COVID-19 protection if you’re immunocompromised or high risk.
04.12.2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and ...
This Is the First Anti-PD-1 Combination Approved as First-Line Treatment for These Patients Merck known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose ...